•  
  •  
  •  
  •  

2025-09-03 04:12:48

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes

Keywords Selected:  INE059A01026

Research

  • ICICI Direct on Cipla: Consolidation breakout signifies resumption of primary up trend...

Stock Report

  • SES ESG Research Pvt Ltd assigns ESG rating of 69.3 to Cipla Ltd
  • Cipla Health takes a humorous spin on real life stories with Astaberry's campaign 'Get the Rich Look'
  • Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassador
  • Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassado
  • Update on USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India
  • Cipla Limited receives USFDA final approval for ANDA Protein-bound Paclitaxel
  • USFDA inspection at manufacturing facility of Medispray in Kundaim, Goa, India
  • Cipla Limited's Kurkumbh facility gets VAI classification from USFDA
  • Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India
  • USFDA inspection at Cipla Ltd's manufacturing facility in Patalganga, Maharashtra, India
  • Cipla Ltd gets 6 observations from USFDA for Goa facility
  • Cipla EU to invest an additional EUR 3 million in Ethris
  • Cipla Ltd recommends final dividend of Rs. 13
  • Cipla Ltd receives 1 observation from USFDA for Kurkumbh facility
  • Cipla Health Ltd completes purchase of a business undertaking from Ivia Beaute Pvt Ltd
  • Cipla Health strengthens its play in beauty and personal care
  • Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in India
  • USFDA completes PAI of Cipla's Qidong unit
  • Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group
  • Cipla EU Ltd to form JV in USA
  • Cipla expands patient reach to remotest towns by furthering investment in GoApptiv
  • Cipla partners with TEACH to create career opportunities for hearing-impaired youth
  • USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
  • Cipla Medpro South Africa Pty Ltd to acquire Actor Pharma Pty Ltd.

Latest Post

  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024